ABBV Jun 2024 70.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.0300

0.0000

(0.00%)

As of 02:22PM EDT. Market open.

Loading interactive chart…

Zacks
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
Investor's Business Daily
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.
Zacks
Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.